263 related articles for article (PubMed ID: 26123662)
1. Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.
Huang J; Lyu H; Wang J; Liu B
Cancer Lett; 2015 Oct; 366(2):160-72. PubMed ID: 26123662
[TBL] [Abstract][Full Text] [Related]
2. Targeting survivin with YM155 (Sepantronium Bromide): a novel therapeutic strategy for paediatric acute myeloid leukaemia.
Smith AM; Little EB; Zivanovic A; Hong P; Liu AK; Burow R; Stinson C; Hallahan AR; Moore AS
Leuk Res; 2015 Apr; 39(4):435-44. PubMed ID: 25659731
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of YM155, a selective survivin suppressant, in combination with cisplatin in hepatoblastoma.
Yu Y; Zhao X; Zhang Y; Kang Y; Wang J; Liu Y
Oncol Rep; 2015 Jul; 34(1):407-14. PubMed ID: 25955434
[TBL] [Abstract][Full Text] [Related]
4. AML sensitivity to YM155 is modulated through AKT and Mcl-1.
de Necochea-Campion R; Diaz Osterman CJ; Hsu HW; Fan J; Mirshahidi S; Wall NR; Chen CS
Cancer Lett; 2015 Sep; 366(1):44-51. PubMed ID: 26118775
[TBL] [Abstract][Full Text] [Related]
5. siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells.
Karami H; Baradaran B; Esfahani A; Estiar MA; Naghavi-Behzad M; Sakhinia M; Sakhinia E
Asian Pac J Cancer Prev; 2013; 14(12):7719-24. PubMed ID: 24460358
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
Yamanaka K; Nakahara T; Yamauchi T; Kita A; Takeuchi M; Kiyonaga F; Kaneko N; Sasamata M
Clin Cancer Res; 2011 Aug; 17(16):5423-31. PubMed ID: 21737502
[TBL] [Abstract][Full Text] [Related]
7. Silencing of survivin using YM155 induces apoptosis and chemosensitization in neuroblastomas cells.
Liang H; Zhang L; Xu R; Ju XL
Eur Rev Med Pharmacol Sci; 2013 Nov; 17(21):2909-15. PubMed ID: 24254560
[TBL] [Abstract][Full Text] [Related]
8. YM155 induces apoptosis through downregulation of specificity protein 1 and myeloid cell leukemia-1 in human oral cancer cell lines.
Sachita K; Yu HJ; Yun JW; Lee JS; Cho SD
J Oral Pathol Med; 2015 Nov; 44(10):785-91. PubMed ID: 25475012
[TBL] [Abstract][Full Text] [Related]
9. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.
Nakahara T; Yamanaka K; Hatakeyama S; Kita A; Takeuchi M; Kinoyama I; Matsuhisa A; Nakano K; Shishido T; Koutoku H; Sasamata M
Anticancer Drugs; 2011 Jun; 22(5):454-62. PubMed ID: 21389848
[TBL] [Abstract][Full Text] [Related]
10. Antitumor effect of YM155, a novel small-molecule survivin suppressant, via mitochondrial apoptosis in human MFH/UPS.
Minoda M; Kawamoto T; Ueha T; Kamata E; Morishita M; Harada R; Toda M; Onishi Y; Hara H; Kurosaka M; Akisue T
Int J Oncol; 2015 Sep; 47(3):891-9. PubMed ID: 26166250
[TBL] [Abstract][Full Text] [Related]
11. Synergistic cytotoxicity of decitabine and YM155 in leukemia cells through upregulation of SLC35F2 and suppression of MCL1 and survivin expression.
Chiou JT; Chang LS
Apoptosis; 2024 Apr; 29(3-4):503-520. PubMed ID: 38066391
[TBL] [Abstract][Full Text] [Related]
12. YM155 induces caspase-8 dependent apoptosis through downregulation of survivin and Mcl-1 in human leukemia cells.
Feng W; Yoshida A; Ueda T
Biochem Biophys Res Commun; 2013 May; 435(1):52-7. PubMed ID: 23618862
[TBL] [Abstract][Full Text] [Related]
13. Survivin selective inhibitor YM155 promotes cisplatin‑induced apoptosis in embryonal rhabdomyosarcoma.
Ueno T; Uehara S; Nakahata K; Okuyama H
Int J Oncol; 2016 May; 48(5):1847-54. PubMed ID: 26983495
[TBL] [Abstract][Full Text] [Related]
14. YM155 reverses cisplatin resistance in head and neck cancer by decreasing cytoplasmic survivin levels.
Kumar B; Yadav A; Lang JC; Cipolla MJ; Schmitt AC; Arradaza N; Teknos TN; Kumar P
Mol Cancer Ther; 2012 Sep; 11(9):1988-98. PubMed ID: 22723337
[TBL] [Abstract][Full Text] [Related]
15. siRNA-mediated inhibition of survivin gene enhances the anti-cancer effect of etoposide in U-937 acute myeloid leukemia cells.
Jafarlou M; Baradaran B; Shanehbandi D; Saedi TA; Jafarlou V; Ismail P; Othman F
Cell Mol Biol (Noisy-le-grand); 2016 May; 62(6):44-9. PubMed ID: 27262801
[TBL] [Abstract][Full Text] [Related]
16. Synergistic antitumor activities of sepantronium bromide (YM155), a survivin suppressant, in combination with microtubule-targeting agents in triple-negative breast cancer cells.
Kaneko N; Yamanaka K; Kita A; Tabata K; Akabane T; Mori M
Biol Pharm Bull; 2013; 36(12):1921-7. PubMed ID: 24432379
[TBL] [Abstract][Full Text] [Related]
17. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma.
Kaneko N; Mitsuoka K; Amino N; Yamanaka K; Kita A; Mori M; Miyoshi S; Kuromitsu S
Clin Cancer Res; 2014 Apr; 20(7):1814-22. PubMed ID: 24486595
[TBL] [Abstract][Full Text] [Related]
18. Survivin family proteins as novel molecular determinants of doxorubicin resistance in organotypic human breast tumors.
Faversani A; Vaira V; Moro GP; Tosi D; Lopergolo A; Schultz DC; Rivadeneira D; Altieri DC; Bosari S
Breast Cancer Res; 2014 May; 16(3):R55. PubMed ID: 24886669
[TBL] [Abstract][Full Text] [Related]
19. YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma.
Gao JZ; Chen FH; Wang L; Wei H; Meng SL
Eur Rev Med Pharmacol Sci; 2015; 19(11):2062-9. PubMed ID: 26125270
[TBL] [Abstract][Full Text] [Related]
20. Targeting Survivin Inhibits Renal Cell Carcinoma Progression and Enhances the Activity of Temsirolimus.
Carew JS; Espitia CM; Zhao W; Mita MM; Mita AC; Nawrocki ST
Mol Cancer Ther; 2015 Jun; 14(6):1404-13. PubMed ID: 25808836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]